Shamekh SIV Solutions, LLC (Detroit, MI) is honored to announce our $5.8 billion global plan for a series of pharmaceutical manufacturing facilities aligned with the executive order signed by President Trump on May 5, 2025. The first of these facilities will be established in the Kingdom of Saudi Arabia. This significant development underscores our unwavering commitment to revolutionizing the life sciences and biopharmaceutical manufacturing sectors in the USA across the Middle East.

Shamekh SIV Solutions facilities are designed to incorporate fully automated IV manufacturing capabilities with cutting-edge AI-driven research and clinical development of novel biopharmaceuticals. Ground-breaking on our flagship facility in the Kingdom of Saudi Arabia is scheduled in the Fall of 2025.

President Trump’s forward-looking views on business and sovereign security has been an inspiration to revolutionize the life sciences and biopharmaceutical manufacturing sectors the USA and across the Middle East. This initiative is poised to enhance local medical solution capabilities, foster innovation, and advance healthcare both regionally and internationally.

Strengthening Supply Chains for National Security

At the heart of this venture lies a critical focus on securing and diversifying supply chains to safeguard national interests. By establishing state-of-the-art manufacturing facilities in Saudi Arabia and the across the Americas, we are reducing dependency on fragile global supply networks and ensuring a resilient, reliable flow of essential medical products. This strategic approach not only bolsters national security but also reinforces U.S. leadership in healthcare innovation and self-sufficiency.

Shamekh SIV Solutions is dedicated to empowering local communities by creating high-quality jobs and investing in workforce development programs. Our facilities will prioritize hiring and training local talent, offering specialized programs to equip employees with cutting-edge skills in biopharmaceutical manufacturing and AI-driven research. This initiative not only supports the regional economy but also ensures a sustainable pipeline of skilled professionals ready to lead the future of healthcare innovation.

Stephen Shaya, M.D., Chairman of the Board and Founder, states, “We extend our profound gratitude to President Trump, Crown Prince Mohammed bin Salman Al Saud, the Administrations of the United States and the Kingdom of Saudi Arabia, and our future partner Alturki Holding for their unwavering support and shared vision in making this endeavor possible. The Trump Administration’s policies and engagements have shown leadership and laid the groundwork for international partnerships and investment opportunities.

As we embark on this transformative journey, we are committed to generating employment, stimulating industrial growth, and contributing to the development of a robust pharmaceutical industry in the Kingdom of Saudi Arabia and the United States. Together with our esteemed partners, we are fortifying global competitiveness and positioning ourselves as leaders in the healthcare sector.

This venture represents a monumental leap forward in our mission to deliver innovative healthcare solutions. By leveraging advanced technologies and fostering international collaborations, we aim to set new standards in biopharmaceutical manufacturing and research, ultimately improving patient outcomes worldwide.”